Latanoprost Aurovitas

Latanoprost, the active ingredient in Latanoprost Aurovitas, is a prostaglandin analog presented as an ophthalmic eye‑drop solution for ocular administration. It acts to increase uveoscleral outflow of aqueous humor, thereby reducing intra‑ocular pressure in adult patients with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Latanoprost Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide for the management of glaucoma and ocular hypertension, under strict quality standards and regulatory compliance.

Latanoprost is a prostaglandin analog used to manage ocular conditions characterized by elevated intra‑ocular pressure.

- Open‑angle glaucoma: reduces intra‑ocular pressure, helping to prevent optic nerve damage. - Ocular hypertension: lowers eye pressure to reduce the risk of progression to glaucoma. - Secondary open‑angle glaucoma: provides pressure reduction in cases secondary to other ocular conditions.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris pigmentation change: gradual darkening of eye colour. - Eye irritation: transient burning or stinging sensation. - Blurred vision: temporary visual disturbance after instillation. - Foreign body sensation: feeling of something in the eye.

Serious or Rare Side Effects: - Severe eye inflammation: uveitis or iritis requiring medical attention. - Allergic reaction: swelling, itching, or rash around the eye. - Corneal edema: swelling of the cornea that can affect vision. - Macular edema: fluid accumulation in the retina, potentially impairing central vision. - Vision loss: sudden decrease in visual acuity. - Persistent ocular pain: ongoing discomfort beyond the initial period.

When prescribing Latanoprost, clinicians should consider several safety measures.

- Monitor intra‑ocular pressure: measure regularly after initiation. - Assess for ocular infections: avoid use if active infection is present. - Avoid contact lenses: discontinue lens wear during treatment. - Use with caution in patients with a history of uveitis: monitor for inflammation. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at room temperature: keep bottle in original packaging, protect from light and moisture.

Latanoprost may interact with other ophthalmic agents, requiring attention to potential additive effects.

Major Interactions (Avoid): - Concomitant use of other prostaglandin analogs: may increase risk of ocular side effects. - Non‑steroidal anti‑inflammatory eye drops: may reduce Latanoprost efficacy. - Systemic carbonic anhydrase inhibitors: additive intra‑ocular pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: combined IOP reduction may require pressure monitoring. - Corticosteroid eye drops: may diminish Latanoprost's pressure‑lowering effect. - Anticholinergic agents: possible reduced outflow response, monitor IOP.